Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Cancer. 2019 Oct 29;126(3):593–601. doi: 10.1002/cncr.32552

Figure 1: Association of starting therapy regimen and survival.

Figure 1:

(A) Five-year EFS rates for starting therapy with an ALL compared to an AML regimen were 73±10% versus 62±14% (p=0.626); (B) five-year OS rates were 78±9% versus 69±14% (p=0.548).